SK286593B6 - Spôsob prípravy nekryštalickej vápenatej soli atorvastatínu - Google Patents

Spôsob prípravy nekryštalickej vápenatej soli atorvastatínu Download PDF

Info

Publication number
SK286593B6
SK286593B6 SK908-2003A SK9082003A SK286593B6 SK 286593 B6 SK286593 B6 SK 286593B6 SK 9082003 A SK9082003 A SK 9082003A SK 286593 B6 SK286593 B6 SK 286593B6
Authority
SK
Slovakia
Prior art keywords
atorvastatin
solution
process according
calcium
crystalline
Prior art date
Application number
SK908-2003A
Other languages
English (en)
Slovak (sk)
Other versions
SK9082003A3 (en
Inventor
Gorazd Sorsak
Original Assignee
Lek Pharmaceutical And Chemical Company D.D.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lek Pharmaceutical And Chemical Company D.D. filed Critical Lek Pharmaceutical And Chemical Company D.D.
Publication of SK9082003A3 publication Critical patent/SK9082003A3/sk
Publication of SK286593B6 publication Critical patent/SK286593B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Obesity (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SK908-2003A 2001-01-23 2002-01-22 Spôsob prípravy nekryštalickej vápenatej soli atorvastatínu SK286593B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SI200100010A SI20814A (sl) 2001-01-23 2001-01-23 Priprava amorfnega atorvastatina
PCT/IB2002/000161 WO2002059087A1 (en) 2001-01-23 2002-01-22 Preparation of non-crystalline atorvastatin calcium

Publications (2)

Publication Number Publication Date
SK9082003A3 SK9082003A3 (en) 2003-12-02
SK286593B6 true SK286593B6 (sk) 2009-01-07

Family

ID=20432812

Family Applications (1)

Application Number Title Priority Date Filing Date
SK908-2003A SK286593B6 (sk) 2001-01-23 2002-01-22 Spôsob prípravy nekryštalickej vápenatej soli atorvastatínu

Country Status (27)

Country Link
US (2) US6750353B2 (https=)
EP (1) EP1373202B1 (https=)
JP (1) JP4336106B2 (https=)
KR (1) KR100882066B1 (https=)
CN (1) CN1260213C (https=)
AT (1) ATE294159T1 (https=)
AU (1) AU2002219455B2 (https=)
BG (1) BG108017A (https=)
BR (1) BR0206637A (https=)
CA (1) CA2435954C (https=)
CZ (1) CZ20031988A3 (https=)
DE (1) DE60203894T2 (https=)
DK (1) DK1373202T3 (https=)
EE (1) EE05270B1 (https=)
ES (1) ES2240748T3 (https=)
HR (1) HRP20030575B1 (https=)
HU (1) HU227535B1 (https=)
IL (2) IL157068A0 (https=)
MX (1) MXPA03006548A (https=)
PL (1) PL209428B1 (https=)
RS (1) RS51010B (https=)
RU (1) RU2324679C2 (https=)
SI (2) SI20814A (https=)
SK (1) SK286593B6 (https=)
UA (1) UA73829C2 (https=)
WO (1) WO2002059087A1 (https=)
ZA (1) ZA200305307B (https=)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
CA2622477A1 (en) 2000-12-27 2002-07-04 Teva Pharmaceutical Industries Ltd. Crystalline forms of atorvastatin
WO2002068335A2 (en) * 2001-02-27 2002-09-06 Council Of Scientific And Industrial Research Essential oil composition for potable water disinfection
SK16002003A3 (sk) 2001-06-29 2004-12-01 Warner-Lambert Company Llc Kryštalické formy vápenatej soli (2:1) [R-(R*,R*)]-2-(4-fluóro- fenyl)-beta,delta-dihydroxy-5-(1-metyletyl)-3-fenyl-4- [(fenylamino)karbonyl]-1H-pyrrol-1-heptánovej kyseliny (atorvastatín)
WO2005033078A1 (en) * 2003-10-07 2005-04-14 Biocon Limited Process for the production of atorvastatin calcium
HU227124B1 (en) * 2001-09-14 2010-07-28 Egis Gyogyszergyar Nyilvanosan Polymorphs of 1-pyrrole derivative, intermediate for the preparation of atorvastatin
CN100379723C (zh) 2002-02-19 2008-04-09 特瓦制药工业有限公司 阿托伐他汀半钙脱溶剂的方法和基本上不含有机溶剂的阿托伐他汀半钙
ITMI20020907A1 (it) * 2002-04-29 2003-10-29 Chemi Spa Processo di preparazione della forma amorfa del sale di calcio della atorvastatina
CA2385529A1 (en) * 2002-05-21 2003-11-21 Bernard Charles Sherman Stable dosage forms comprising atorvastatin calcium
CA2520740C (en) * 2003-04-11 2012-06-05 Lek Pharmaceuticals D.D. Process for the preparation of amorphous calcium salt of atorvastatin
US7790197B2 (en) 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US7655692B2 (en) 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
EP1648903A2 (en) 2003-07-02 2006-04-26 Egis Gyogyszergyar Rt. Process for the preparation of amorphous form of a platelet aggregation inhibitor drug
AU2003247327A1 (en) * 2003-07-15 2005-01-28 Eos Eczacibasi Ozgun Kimyasal Urunler Sanyi Ve Ticaret A.S. Process for the preparation of amortphous atorvastatin calcium without interconversion of any crystalline form
JP2007517028A (ja) * 2003-12-29 2007-06-28 レツク・フアーマシユーテイカルズ・デー・デー 非晶質の（４ｒ−シス）−６−［２−［３−フェニル−４−（フェニルカルバモイル）−２−（４−フルオロフェニル）−５−（１−メチルエチル）−ピロール−１−イル］−エチル］−２，２−ジメチル−［１，３］−ジオキサン−４−イル−酢酸を調製する方法
ATE545629T1 (de) 2004-03-17 2012-03-15 Ranbaxy Lab Ltd Verfahren zur herstellung von atorvastatin- calcium in amorpher form
US7875731B2 (en) 2004-05-05 2011-01-25 Pfizer Inc. Salt forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β, δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)Carbonyl]-1H-pyrrole-1-heptanoic acid
US8044086B2 (en) * 2004-07-16 2011-10-25 Lek Pharmaceuticals D.D. Oxidative degradation products of atorvastatin calcium
CA2701710C (en) 2004-07-20 2013-08-27 Warner-Lambert Company Llc Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)
WO2006011155A1 (en) * 2004-07-26 2006-02-02 Apollo International Limited One pot process for amorphous atorvastain calcium
US7645888B2 (en) 2004-08-27 2010-01-12 Biocon Limited Process for the production of amorphous atorvastatin calcium
AU2005298383A1 (en) 2004-10-28 2006-05-04 Warner-Lambert Company Llc Process for forming amorphous atorvastatin
ES2270722B1 (es) * 2005-09-15 2008-03-01 Ercros Industrial, S.A. Procedimiento para la obtencion de atorvastatina calcica amorfa.
US20090216029A1 (en) * 2005-09-16 2009-08-27 Yatendra Kumar Process for the production of atorvastatin calcium in amorphous form
CA2547216A1 (en) 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
ATE466840T1 (de) 2005-11-21 2010-05-15 Warner Lambert Co Neue formen von är-(r*,r*)ü-2-(4-fluorphenyl)-b,d-dihydroxy-5-( -methylethyl)-3-phenyl-4- ä(phenylamino)carbonylü-1h-pyrrol-1-heptansäure magnesium
EP1810667A1 (en) 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising amorphous atorvastatin
EP1979313A1 (en) * 2006-01-31 2008-10-15 Jubilant Organosys Limited Process for the preparation of amorphous atorvastatin calcium salt
CN100406438C (zh) * 2006-06-30 2008-07-30 浙江新东港药业股份有限公司 一种无定型阿伐他汀钙的制备方法
US20100113802A1 (en) * 2006-11-02 2010-05-06 Cadila Pharmaceuticals Limited Process for preparing amorphous atorvastatin hemi calcium salt and its itermediate
KR100833439B1 (ko) * 2007-01-02 2008-05-29 씨제이제일제당 (주) 비결정형 아토르바스타틴 칼슘의 개선된 제조방법
WO2009052246A1 (en) 2007-10-17 2009-04-23 Ovokaitys, Todd, F. Process for the modification of the solid state of a compound and co-amorphous compositions produced with same
WO2009139730A1 (en) * 2008-05-13 2009-11-19 Ulkar Kimya San. Ve Tic. A.S. Preparation of novel non-crystalline forms of atorvastatin calcium
KR101050722B1 (ko) 2008-12-02 2011-07-21 대웅바이오 주식회사 무정형 아토르바스타틴 칼슘염의 제조방법
US8115015B2 (en) * 2009-01-26 2012-02-14 Cadila Healthcare Limited Process for the preparation of amorphous atorvastatin calcium
US20130041162A1 (en) * 2010-04-19 2013-02-14 Dsm Sinochem Pharmaceuticals Netherlands B.V. Production of atorvastatin low in ether impurities
HUP1000299A2 (hu) 2010-06-08 2012-02-28 Nanoform Cardiovascular Therapeutics Ltd Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra
CN102796036B (zh) * 2012-09-12 2014-06-04 江苏阿尔法药业有限公司 一种阿托伐他汀钙的制备方法
US10202598B2 (en) 2014-05-30 2019-02-12 Todd Frank Ovokaitys Methods and systems for generation, use, and delivery of activated stem cells
US10384985B2 (en) 2014-06-06 2019-08-20 B.K. Consultants, Inc. Methods and compositions for increasing the yield of, and beneficial chemical composition of, certain plants
US10040728B2 (en) 2014-06-06 2018-08-07 Todd Frank Ovokaitys Methods and compositions for increasing the bioactivity of nutrients
CN113321607A (zh) * 2020-02-28 2021-08-31 北京福元医药股份有限公司沧州分公司 一种阿托伐他汀钙中间体的纯化方法
WO2022126109A1 (en) 2020-12-08 2022-06-16 Ovokaitys Todd Frank Methods and systems for increased production of stem cells

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5216174A (en) 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5245047A (en) 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5149837A (en) 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5097045A (en) 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5124482A (en) 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5103024A (en) 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en) 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5798375A (en) * 1995-07-03 1998-08-25 Sankyo Company, Limited Treatment of arteriosclerosis and xanthoma
HRP960312B1 (en) * 1995-07-17 2001-10-31 Warner Lambert Co NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
HRP960313B1 (en) 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
KR100389518B1 (ko) * 1995-07-17 2003-11-15 워너-램버트 캄파니 엘엘씨 결정질[r-(r*,r*)]-2-(4-플루오로페닐)-베타,델타-디히드록시-5-(1-메틸에틸)-3-페닐-4-[(페닐아미노)카르보닐]-1h-피롤-1-헵탄산헤미칼슘염(아토르바스타틴)
US6087511A (en) * 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
IN191236B (https=) * 1999-05-25 2003-10-11 Ranbaxy Lab Ltd

Also Published As

Publication number Publication date
ATE294159T1 (de) 2005-05-15
PL361763A1 (en) 2004-10-04
US7074940B2 (en) 2006-07-11
IL157068A (en) 2009-09-01
KR20030077003A (ko) 2003-09-29
SI20814A (sl) 2002-08-31
JP4336106B2 (ja) 2009-09-30
YU56803A (sh) 2006-05-25
CN1487921A (zh) 2004-04-07
UA73829C2 (en) 2005-09-15
HUP0302797A3 (en) 2009-09-28
EP1373202A1 (en) 2004-01-02
KR100882066B1 (ko) 2009-02-10
DE60203894D1 (de) 2005-06-02
HU227535B1 (en) 2011-08-29
AU2002219455B2 (en) 2007-04-26
RU2003124962A (ru) 2005-01-10
CZ20031988A3 (cs) 2003-11-12
BR0206637A (pt) 2004-08-03
US6750353B2 (en) 2004-06-15
PL209428B1 (pl) 2011-08-31
WO2002059087A1 (en) 2002-08-01
RU2324679C2 (ru) 2008-05-20
CA2435954A1 (en) 2002-08-01
SK9082003A3 (en) 2003-12-02
MXPA03006548A (es) 2004-10-15
HUP0302797A2 (hu) 2003-11-28
EE200300333A (et) 2003-10-15
US20030109569A1 (en) 2003-06-12
BG108017A (bg) 2004-08-31
HRP20030575B1 (hr) 2011-10-31
ES2240748T3 (es) 2005-10-16
SI1373202T1 (sl) 2005-12-31
DE60203894T2 (de) 2006-01-19
US20040072895A1 (en) 2004-04-15
CA2435954C (en) 2008-06-03
ZA200305307B (en) 2004-07-09
IL157068A0 (en) 2004-02-08
EE05270B1 (et) 2010-02-15
CN1260213C (zh) 2006-06-21
EP1373202B1 (en) 2005-04-27
RS51010B (sr) 2010-10-31
HRP20030575A2 (en) 2005-06-30
JP2005503997A (ja) 2005-02-10
DK1373202T3 (da) 2005-05-17

Similar Documents

Publication Publication Date Title
SK286593B6 (sk) Spôsob prípravy nekryštalickej vápenatej soli atorvastatínu
AU2002219455A1 (en) Preparation of non-crystalline atorvastatin calcium
RS56803B1 (sr) Postupak za proizvodnju 2-[4-(3-ili2-fluorobenziloksi)benzilamino] propanamida sa visokim stepenom čistoće
EP2192112B1 (en) Process for preparing atorvastatin hemi-calcium Form I
EP1341785B1 (en) Hydrolysis of r(r*,r*)-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4- [(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid esters with calcium hydroxide
RU2247113C2 (ru) Способ получения аморфного аторвастатина
AU2002232891A1 (en) Hydrolysis of [R(R*,R*)]-2-(4-fluorophenyl)-beta,delta -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino) carbonyl]-1H-pyrrole-1-heptanoic acid esters with calcium hydroxide
EP1424324A1 (en) Crystalline form F of Atorvastatin hemi-calcium salt
AU2009350099A1 (en) Crystalline Form I rosuvastatin zinc salt
WO2006048888A1 (en) Novel process for the preparation of amorphous atorvastatin calcium salt
EA024416B1 (ru) Кристаллические формы цинковой соли розувастатина
MX2008000375A (en) Crystalline form of atorvastatin calcium stable after storage

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20150122